The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice
Leticia Forny Germano(Lunenfeld-Tanenbaum Research Institute), Daniel J. Drucker(University of Toronto), Dianne Matthews(Sinai Health System), Laurie L. Baggio(Sinai Health System), Fiona Cui(Lunenfeld-Tanenbaum Research Institute), Jacqueline A. Koehler(Lunenfeld-Tanenbaum Research Institute), Nikolaj Rittig(Steno Diabetes Centers), Xiemin Cao(Lunenfeld-Tanenbaum Research Institute), Chi Kin Wong(Lunenfeld-Tanenbaum Research Institute)
Cited by 37
Related Papers
The role of gut hormones in glucose homeostasis
|Journal of Clinical Investigation|2007|611
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
|Endocrine Reviews|2014|602
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
|Diabetes Care|2003|578
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
|Endocrine Reviews|2020|268